GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Algernon Pharmaceuticals Inc (XCNQ:AGN) » Definitions » Short Interest

Algernon Pharmaceuticals (XCNQ:AGN) Short Interest


View and export this data going back to 2016. Start your Free Trial

What is Algernon Pharmaceuticals Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Algernon Pharmaceuticals's Short Interest

For the Biotechnology subindustry, Algernon Pharmaceuticals's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Algernon Pharmaceuticals's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Algernon Pharmaceuticals's Short Interest distribution charts can be found below:

* The bar in red indicates where Algernon Pharmaceuticals's Short Interest falls into.


;
;

Algernon Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Algernon Pharmaceuticals Inc (XCNQ:AGN) » Definitions » Short Interest
Comparable Companies
XCNQ:ENBI XCNQ:HEAL XCNQ:MBIO XCNQ:MYND XCNQ:RIZE XCNQ:NURL TSX:APLI XCNQ:MOOD TSXV:WAVE XCNQ:NSHS VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
AGNPF:USA AGW0:Germany
Address
601 West Broadway, Suite 400, Vancouver, BC, CAN, V5Z 4C2
Website
https://www.algernonpharmaceuticals.com
Algernon Pharmaceuticals Inc is a clinical-stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis, and chronic cough. The company's business model is capital efficient and strives to deliver maximum shareholder value. Algernon's approach to drug discovery is based on the concept of drug repurposing. It operates in two reportable segments: the development of repurposed therapeutic drugs in Canada, and the facilitation of the Company's drug candidates into off-label phase II clinical trials (humans) in Australia.
Executives
Christopher Moreau Director, Senior Officer
Christopher Scott Bryan Senior Officer
James Kinley Senior Officer
Harry J.f. Bloomfield Director
Rajpaul Attariwala Director
Mark Williams Director
Howard Gutman Director
Michael Sadhra Senior Officer
Kulwant Malhi 10% Security Holder

Algernon Pharmaceuticals Headlines

No Headlines